Effect of Different Dosing Regimens of Tadalafil or Tamsulosin Combined With 5α-Reductase Inhibitors on Urinary and Sexual Outcomes in Benign Prostatic Hyperplasia
Key facts
- Who runs it
- Beni-Suef University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 240 people enrolled
- Ended
- 1 Jan 2026
- Type of study
- Interventional, 6 groups
- Treatments tested
- Tamsulosin
- Tadalafil
- 5-Alpha Reductase Inhibitor
- Record updated
- 20 July 2026
Who can take part
- Age
- 50 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Male participants aged 50 years or older
- Newly diagnosed with benign prostatic hyperplasia (BPH)
- Moderate to severe lower urinary tract symptoms (LUTS), defined as International Prostate Symptom Score (IPSS) > 7
- Prostate volume >40 mL confirmed by transrectal ultrasonography (TRUS)
- Sexually active with a baseline International Index of Erectile Function-Erectile Function (IIEF-EF) score >10
- Prostate-specific antigen (PSA) <4 ng/mL and no suspicious findings on digital rectal examination (DRE)
- Able and willing to provide written informed consent
Who cannot take part
- Previous prostate surgery
- Current use of medications known to significantly affect sexual function
- Concurrent use of nitrates or contraindicated antihypertensive medications
- History of prostate cancer
- Abnormal digital rectal examination suggestive of malignancy
- Uncontrolled diabetes mellitus
- Uncontrolled cardiovascular disease
- Neurological disorders affecting bladder function
- Renal impairment
- Hepatic impairment
- Active urinary tract infection
- Known hypersensitivity to tamsulosin, tadalafil, or 5-alpha reductase inhibitors
- Severe erectile dysfunction (IIEF-EF score ≤10)
- Bladder stones or other significant urological pathology
- Patients actively seeking fertility treatment
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Benign prostatic hyperplasia (BPH) is a common condition among aging men that causes lower urinary tract symptoms (LUTS) and may negatively affect sexual function. This randomized single-blind controlled clinical trial compares the efficacy, safety, and sexual outcomes of different dosing regimens of tadalafil or tamsulosin combined with 5-alpha reductase inhibitors (5ARIs) in men with BPH and enlarged prostate volume. A total of 240 participants were randomly assigned to six treatment groups and followed for 12 weeks. Changes in urinary symptoms, erectile function, ejaculatory function, prostate volume, prostate-specific antigen (PSA), urinary flow rate, post-void residual volume, and adverse events were evaluated to determine the optimal combination regimen.
The 6 groups in the trial
- Tamsulosin daily + 5ARI dailyTreatment being tested
Participants received tamsulosin 0.4 mg once daily in combination with a 5-alpha reductase inhibitor administered once daily for 12 weeks.
Treatment: Tamsulosin and 5-Alpha Reductase Inhibitor
- Tamsulosin daily + 5ARI every other dayTreatment being tested
Participants received tamsulosin 0.4 mg once daily combined with a 5-alpha reductase inhibitor administered every other day for 12 weeks.
Treatment: Tamsulosin and 5-Alpha Reductase Inhibitor
- Tamsulosin every other day + 5ARI every other dayTreatment being tested
Participants received tamsulosin 0.4 mg every other day combined with a 5-alpha reductase inhibitor administered every other day for 12 weeks.
Treatment: Tamsulosin and 5-Alpha Reductase Inhibitor
- Tadalafil daily + 5ARI dailyTreatment being tested
Participants received tadalafil 5 mg once daily in combination with a 5-alpha reductase inhibitor administered once daily for 12 weeks.
Treatment: Tadalafil and 5-Alpha Reductase Inhibitor
- Tadalafil daily + 5ARI every other dayTreatment being tested
Participants received tadalafil 5 mg once daily combined with a 5-alpha reductase inhibitor administered every other day for 12 weeks.
Treatment: Tadalafil and 5-Alpha Reductase Inhibitor
- Tadalafil every other day + 5ARI every other dayTreatment being tested
Participants received tadalafil 5 mg every other day combined with a 5-alpha reductase inhibitor administered every other day for 12 weeks.
Treatment: Tadalafil and 5-Alpha Reductase Inhibitor
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- "Effect of Different Dosing Regimens of Tadalafil or Tamsulosin Combined With 5α-Reductase Inhibitors on Urinary and Sexual Outcomes in Benign Prostatic Hyperplasia: A Comparative Clinical Trial Study"
- Record updated
- 20 July 2026